Kramer JA - Search Results

1

The application of discovery toxicology and pathology towards the design of safer pharmaceutical lead candidates.

Kramer JA, Sagartz JE, Morris DL. Kramer JA, et al. Nat Rev Drug Discov. 2007 Aug;6(8):636-49. doi: 10.1038/nrd2378. Nat Rev Drug Discov. 2007. PMID: 17643090 Review.

2

Acute lymphoid and gastrointestinal toxicity induced by selective p38alpha map kinase and map kinase-activated protein kinase-2 (MK2) inhibitors in the dog.

Morris DL, O'Neil SP, Devraj RV, Portanova JP, Gilles RW, Gross CJ, Curtiss SW, Komocsar WJ, Garner DS, Happa FA, Kraus LJ, Nikula KJ, Monahan JB, Selness SR, Galluppi GR, Shevlin KM, Kramer JA, Walker JK, Messing DM, Anderson DR, Mourey RJ, Whiteley LO, Daniels JS, Yang JZ, Rowlands PC, Alden CL, Davis JW 2nd, Sagartz JE. Morris DL, et al. Among authors: kramer ja. Toxicol Pathol. 2010 Jun;38(4):606-18. doi: 10.1177/0192623310367807. Epub 2010 May 6. Toxicol Pathol. 2010. PMID: 20448081

3

Differential display in rat livers treated for 13 weeks with phenobarbital implicates a role for metabolic and oxidative stress in nongenotoxic carcinogenicity.

Elrick MM, Kramer JA, Alden CL, Blomme EA, Bunch RT, Cabonce MA, Curtiss SW, Kier LD, Kolaja KL, Rodi CP, Morris DL. Elrick MM, et al. Among authors: kramer ja. Toxicol Pathol. 2005;33(1):118-26. doi: 10.1080/01926230590888298. Toxicol Pathol. 2005. PMID: 15805063

4

In vivo toxicology of excipients commonly employed in drug discovery in rats.

Gopinathan S, O'Neill E, Rodriguez LA, Champ R, Phillips M, Nouraldeen A, Wendt M, Wilson AGE, Kramer JA. Gopinathan S, et al. Among authors: kramer ja. J Pharmacol Toxicol Methods. 2013 Sep-Oct;68(2):284-295. doi: 10.1016/j.vascn.2013.02.009. Epub 2013 Mar 14. J Pharmacol Toxicol Methods. 2013. PMID: 23499653

5

Early toxicology signal generation in the mouse.

Kramer JA, O'Neill E, Phillips ME, Bruce D, Smith T, Albright MM, Bellum S, Gopinathan S, Heydorn WE, Liu X, Nouraldeen A, Payne BJ, Read R, Vogel P, Yu XQ, Wilson AG. Kramer JA, et al. Toxicol Pathol. 2010 Apr;38(3):452-71. doi: 10.1177/0192623310364025. Epub 2010 Mar 19. Toxicol Pathol. 2010. PMID: 20305093

6

The role of investigative molecular toxicology in early stage drug development.

Gross CJ, Kramer JA. Gross CJ, et al. Among authors: kramer ja. Expert Opin Drug Saf. 2003 Mar;2(2):147-59. doi: 10.1517/14740338.2.2.147. Expert Opin Drug Saf. 2003. PMID: 12904115 Review.

7

Development of a high-throughput human HepG(2) dual luciferase assay for detection of metabolically activated hepatotoxicants and genotoxicants.

Liu X, Kramer JA, Hu Y, Schmidt JM, Jiang J, Wilson AG. Liu X, et al. Among authors: kramer ja. Int J Toxicol. 2009 May-Jun;28(3):162-76. doi: 10.1177/1091581809337166. Int J Toxicol. 2009. PMID: 19546255

8

Toxicogenomics: an opportunity to optimise drug development and safety evaluation.

Kramer JA, Kolaja KL. Kramer JA, et al. Expert Opin Drug Saf. 2002 Sep;1(3):275-86. doi: 10.1517/14740338.1.3.275. Expert Opin Drug Saf. 2002. PMID: 12904143 Review.

9

Development of a highthroughput yeast-based assay for detection of metabolically activated genotoxins.

Liu X, Kramer JA, Swaffield JC, Hu Y, Chai G, Wilson AG. Liu X, et al. Among authors: kramer ja. Mutat Res. 2008 May 31;653(1-2):63-9. doi: 10.1016/j.mrgentox.2008.03.006. Epub 2008 Apr 1. Mutat Res. 2008. PMID: 18485802

10

Pharmacokinetic/pharmacodynamic modelling of 2-acetyl-4(5)-tetrahydroxybutyl imidazole-induced peripheral lymphocyte sequestration through increasing lymphoid sphingosine 1-phosphate.

Yu XQ, Kramer J, Moran L, O'Neill E, Nouraldeen A, Oravecz T, Wilson AG. Yu XQ, et al. Xenobiotica. 2010 May;40(5):350-6. doi: 10.3109/00498251003611376. Xenobiotica. 2010. PMID: 20175664

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

97 results

Search Page